How to start a patient or support switch to NEXTSTELLIS®

NEXTSTELLIS offers women contraceptive efficacy with a predictable bleeding profile AND good tolerability – benefits that appeal to women at any point along their reproductive health journey. Whether your patients are considering birth control for the first time, or switching to a better match for the long-term, NEXTSTELLIS could be the right option.

Instructions for starting or switching to

Information for your patients using NEXTSTELLIS

To prevent pregnancy, patients should be instructed to take NEXTSTELLIS exactly as prescribed; 1 tablet daily for 28 consecutive days; 1 pink (active) tablet daily during the first 24 days and 1 white (inert) tablet daily during the following 4 days. Tablets must be taken every day at about the same time so that the interval between 2 tablets is always 24 hours.1 For patient instructions for starting NEXTSTELLIS and for missed pills, see the full Prescribing Information.



  • In women with irregular menstrual cycles, pregnancy testing may be necessary before initiation of this product

Day 1 Start:

  • Take the first pink active tablet on the first day of menses
  • Take subsequent pink active tablets once daily at the same time each day for 24 days
  • Take 1 white inert tablet daily for 4 days and at the same time of day that active tablets were taken
  • Begin each subsequent 28-day pack on the same day of the week as the first cycle pack (i.e., on the day after taking the last tablet)

If not starting on the first day of menses, use a nonhormonal contraceptive (e.g., condoms and/or spermicide) as backup until 1 active tablet has been taken daily for 7 days in a row.

  • Start NEXTSTELLIS on the day when the new pack of the previous COC would have started

  • Start NEXTSTELLIS the day after the last tablet was taken

  • Start NEXTSTELLIS on the day when the next application, insertion, or injection would have been scheduled

  • Start NEXTSTELLIS on the day of removal

Starting NEXTSTELLIS after delivery (>20 weeks gestation)

  • Must not start earlier than 4 weeks after delivery (due to increased risk for thromboembolism)
  • If menstrual cycles have returned, follow instructions for “Starting NEXTSTELLIS in females with no current use of hormonal contraception”
  • If menstrual cycles have not resumed, consider the possibility of ovulation and pregnancy. If not pregnant, use additional nonhormonal contraception for the first 7 days of NEXTSTELLIS use

Starting NEXTSTELLIS after abortion or miscarriage

If ≤14 weeks gestation

  • Within the first 7 days of complete first trimester abortion or miscarriage, use additional nonhormonal contraception for the next 7 days
  • After the first 7 days, follow instructions for “Starting NEXTSTELLIS in females with no current use of hormonal contraception”

If >14 weeks but ≤20 weeks gestation

  • After 4 weeks following second trimester abortion or miscarriage. Consider duration of pregnancy and increased risk for thromboembolism
  • If menstrual cycles have returned, follow instructions for “Starting NEXTSTELLIS in females with no current use of hormonal contraception”
  • If menstrual cycles have not resumed, consider the possibility of ovulation and pregnancy. If not pregnant, use additional nonhormonal contraception for the first 7 days of NEXTSTELLIS use

Resource for patient counseling


For more information on our product availability, savings program,
sampling, or for details on our patient support services.


IMPORTANT SAFETY INFORMATION FOR NEXTSTELLIS® (drospirenone and estetrol tablets 3 mg/14.2 mg)


See full prescribing information for complete boxed warning.

  • Females over 35 years old who smoke should not use NEXTSTELLIS
  • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.



These highlights do not include all the information needed to use NEXTSTELLIS safely and effectively. See full prescribing information for NEXTSTELLIS.

NEXTSTELLIS (drospirenone and estetrol tablets), for oral use
Initial U.S. Approval: 2021



NEXTSTELLIS is a combination of drospirenone, a progestin, and estetrol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy.



NEXTSTELLIS may be less effective in females with a BMI ≥30 kg/m2. In females with BMI ≥30 kg/m2, decreasing effectiveness may be associated with increasing BMI.



  • Take one tablet by mouth at the same time every day.
  • Take tablets in the order directed on the blister pack.



NEXTSTELLIS consists of 28 tablets in the following order:

  • 24 pink active tablets each containing drospirenone 3 mg and estetrol 14.2 mg
  • 4 white inert tablets



  • A high risk of arterial or venous thrombotic diseases
  • Current or history of a hormonally-sensitive malignancy (e.g., breast cancer)
  • Hepatic adenoma, hepatocellular carcinoma, acute hepatitis or decompensated cirrhosis
  • Co-administration with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir
  • Abnormal uterine bleeding that has an undiagnosed etiology
  • Renal impairment
  • Adrenal insufficiency



  • Thromboembolic Disorders and Other Vascular Problems: Stop NEXTSTELLIS if a thrombotic or thromboembolic event occurs. Start no earlier than 4 weeks after delivery. Consider all cardiovascular risk factors before initiating in any female, particularly in the presence of multiple risk factors.
  • Hyperkalemia: Check serum potassium concentration during the first NEXTSTELLIS treatment cycle in females on long-term treatment with medications that may increase serum potassium concentration.
  • Hypertension: Monitor blood pressure periodically and stop use if blood pressure rises significantly.
  • Migraine: Discontinue if new, recurrent, persistent, or severe migraines occur.
  • Hormonally-Sensitive Malignancy: Discontinue NEXTSTELLIS if a hormonally-sensitive malignancy is diagnosed.
  • Liver Disease: Withhold or permanently discontinue for persistent or significant elevation of liver enzymes.
  • Glucose Tolerance and Hypertriglyceridemia: Monitor glucose in females with prediabetes or diabetes. Consider an alternate contraceptive method for females with hypertriglyceridemia.
  • Gallbladder Disease and Cholestasis: Consider discontinuing NEXTSTELLIS in females with symptomatic gallbladder or cholestatic disease.
  • Bleeding Irregularities and Amenorrhea: May cause irregular bleeding or amenorrhea. Evaluate for other causes if symptoms persist.



Most common adverse reactions (≥2%): Bleeding irregularities, mood disturbance, headache, breast symptoms, dysmenorrhea, acne, weight increased, and libido decreased



  • CYP3A Inducers: May lead to contraceptive failure and/or increase breakthrough bleeding. Avoid concomitant use. If concomitant use is unavoidable, use an alternative or back-up contraceptive method during co-administration and up to 28 days after discontinuation of the CYP3A inducer.
  • See full Prescribing Information for additional clinically significant drug interactions.



  • Pregnancy: Discontinue if pregnancy occurs.
  • Lactation: Advise postpartum females that NEXTSTELLIS can decrease milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or

See PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

BMI=body mass index; COC=combined oral contraceptive; EU=European Union; HDL=high-density lipoprotein; LDL=low-density lipoprotein; LNG=levonorgestrel.



1. NEXTSTELLIS [package insert]. Raleigh, NC: Mayne Pharma; April 2021.